APOE and Alzheimer disease: Together, carrying a SORL1 PTV or HPV expedited AAO by respectively 6 years (95%CI −10– −2) and 9 years (95%CI −13– −1.7) for APOE-ε4-negative AD cases, by respectively 9 (95%CI −10 – −6) and 7 (95%CI −8– −4) years for APOE-ε4-heterozyous cases, and by respectively 4 (95%CI −6–NA) and 5.5 (95%CI −8–NA) years for APOE-ε4/ε4 cases.